Sanofi Gross Profit 2012-2025 | SNY
Sanofi annual/quarterly gross profit history and growth rate from 2012 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Sanofi gross profit for the quarter ending December 31, 2025 was $9.766B, a 73.23% increase year-over-year.
- Sanofi gross profit for the twelve months ending December 31, 2025 was $38.091B, a 13.26% increase year-over-year.
- Sanofi annual gross profit for 2025 was $38.091B, a 13.26% increase from 2024.
- Sanofi annual gross profit for 2024 was $33.633B, a 3.52% decline from 2023.
- Sanofi annual gross profit for 2023 was $34.859B, a 4.39% increase from 2022.
|
Sanofi Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2025 | $38,091 |
| 2024 | $33,633 |
| 2023 | $34,859 |
| 2022 | $33,393 |
| 2021 | $31,849 |
| 2020 | $28,800 |
| 2019 | $28,734 |
| 2018 | $28,630 |
| 2017 | $27,797 |
| 2016 | $26,565 |
| 2015 | $26,585 |
| 2014 | $30,680 |
| 2013 | $29,642 |
| 2012 | $31,945 |
| 2011 | $33,644 |
|
Sanofi Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2025-12-31 | $9,766 |
| 2025-09-30 | $11,406 |
| 2025-06-30 | $8,789 |
| 2025-03-31 | $8,130 |
| 2024-12-31 | $5,638 |
| 2024-09-30 | $11,075 |
| 2024-06-30 | $8,583 |
| 2024-03-31 | $8,337 |
| 2023-12-31 | $8,779 |
| 2023-09-30 | $9,640 |
| 2023-06-30 | $8,084 |
| 2023-03-31 | $8,355 |
| 2022-12-31 | $7,996 |
| 2022-09-30 | $9,374 |
| 2022-06-30 | $7,973 |
| 2022-03-31 | $8,050 |
| 2021-09-30 | $8,951 |
| 2021-06-30 | |
| 2021-03-31 | $7,477 |
| 2020-09-30 | $7,835 |
| 2020-03-31 | $7,117 |
| 2019-09-30 | $7,547 |
| 2019-03-31 | $6,923 |
| 2018-03-31 | $6,860 |
| 2017-12-31 | $6,943 |
| 2017-09-30 | $7,686 |
| 2017-06-30 | $6,654 |
| 2017-03-31 | $6,514 |
| 2016-12-31 | $6,708 |
| 2016-09-30 | $7,275 |
| 2016-06-30 | $6,535 |
| 2016-03-31 | $6,047 |
| 2015-09-30 | $7,434 |
| 2015-06-30 | $7,216 |
| 2014-06-30 | $7,597 |
| 2013-06-30 | $7,066 |
| 2012-06-30 | $8,204 |
| 2012-03-31 | $7,803 |
| 2011-12-31 | $7,948 |
| 2011-09-30 | $7,988 |
| 2011-06-30 | $7,960 |
| 2011-03-31 | $8,191 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $112.219B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |